Shares of Medicure Inc. (CVE:MPH – Get Free Report) reached a new 52-week high during trading on Tuesday . The stock traded as high as C$2.74 and last traded at C$2.74, with a volume of 900 shares trading hands. The stock had previously closed at C$2.69.
Medicure Trading Down 4.0%
The stock has a market cap of C$27.45 million, a PE ratio of -3.65 and a beta of 0.93. The company’s fifty day moving average is C$1.76 and its 200-day moving average is C$1.35. The company has a debt-to-equity ratio of 6.02, a current ratio of 0.97 and a quick ratio of 1.28.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Featured Articles
- Five stocks we like better than Medicure
- DraftKings Falls 7.6%: Is Kalshi’s NFL Lead Really That Big?
- Gaming Your Portfolio: Should You Add Take-Two Ahead of GTA 6’s November Launch?
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
